Pasithea Therapeutics Corp. (KTTAW) Cash from Financing Activities (2021 - 2026)

Pasithea Therapeutics has disclosed Cash from Financing Activities across 5 years of filings, most recently posting $8476.0 for Q2 2026.

• In Q2 2026, Cash from Financing Activities fell 99.85% year-over-year to $8476.0; the TTM figure through Jun 2026 stood at $56.3 million (up 683.26% YoY), while the FY2025 annual figure was $63.5 million, up 1306.02% from the prior year.
• Cash from Financing Activities came in at $8476.0 for Q2 2026 at Pasithea Therapeutics, up from $750.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $56.4 million in Q4 2025 to a low of -$3.9 million in Q3 2023.
• Average Cash from Financing Activities over 4 years is $6.0 million, with a median of $4613.0 recorded in 2026.
• Year-over-year, Cash from Financing Activities soared 239682.21% in 2025 and slumped 99.95% in 2026.
• Over 4 years, Cash from Financing Activities stood at -$3.9 million in 2023, then soared by 99.39% to -$23550.0 in 2024, then soared by 239682.21% to $56.4 million in 2025, then slumped by 99.98% to $8476.0 in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $8476.0 in Q2 2026, $750.0 in Q1 2026, and $56.4 million in Q4 2025.